Hdl Handle:
http://hdl.handle.net/10147/302428
Title:
Pharmacotherapy at the end-of-life.
Authors:
O'Mahony, Denis; O'Connor, Marie N
Affiliation:
Department of Medicine, University College Cork, University Hospital, Wilton, Ireland. denis.omahony@hse.ie
Citation:
Pharmacotherapy at the end-of-life. 2011, 40 (4):419-22 Age Ageing
Publisher:
Age and ageing
Journal:
Age and ageing
Issue Date:
Jul-2011
URI:
http://hdl.handle.net/10147/302428
DOI:
10.1093/ageing/afr059
PubMed ID:
21622981
Abstract:
Older people reaching end-of-life status are particularly at risk from inter-related adverse effects of pharmacotherapy, including polypharmacy, inappropriate medications and adverse drug events. These adverse effects of pharmacotherapy may be highly detrimental, as well as highly expensive. End-of-life pharmacotherapy is sometimes perceived to be complex and challenging, probably unnecessarily. This relates in part to the poorly developed evidence base and lack of high-quality research in this area. In this article, we deal with some of the key issues relating to pharmacotherapy in end-of-life patients, namely (i) the guiding principles of drug selection, (ii) the main drugs and drug classes that are best avoided, (iii) the benefits of 'oligopharmacy' (i.e. deliberate avoidance of polypharmacy) in end-of-life patients.
Item Type:
Article
Language:
en
MeSH:
Aged; Aged, 80 and over; Aging; Drug Therapy; Evidence-Based Medicine; Frail Elderly; Humans; Inappropriate Prescribing; Life Expectancy; Palliative Care; Patient Selection; Polypharmacy; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention
ISSN:
1468-2834

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Mahony, Denisen_GB
dc.contributor.authorO'Connor, Marie Nen_GB
dc.date.accessioned2013-09-27T13:05:13Z-
dc.date.available2013-09-27T13:05:13Z-
dc.date.issued2011-07-
dc.identifier.citationPharmacotherapy at the end-of-life. 2011, 40 (4):419-22 Age Ageingen_GB
dc.identifier.issn1468-2834-
dc.identifier.pmid21622981-
dc.identifier.doi10.1093/ageing/afr059-
dc.identifier.urihttp://hdl.handle.net/10147/302428-
dc.description.abstractOlder people reaching end-of-life status are particularly at risk from inter-related adverse effects of pharmacotherapy, including polypharmacy, inappropriate medications and adverse drug events. These adverse effects of pharmacotherapy may be highly detrimental, as well as highly expensive. End-of-life pharmacotherapy is sometimes perceived to be complex and challenging, probably unnecessarily. This relates in part to the poorly developed evidence base and lack of high-quality research in this area. In this article, we deal with some of the key issues relating to pharmacotherapy in end-of-life patients, namely (i) the guiding principles of drug selection, (ii) the main drugs and drug classes that are best avoided, (iii) the benefits of 'oligopharmacy' (i.e. deliberate avoidance of polypharmacy) in end-of-life patients.en_GB
dc.language.isoenen
dc.publisherAge and ageingen_GB
dc.rightsArchived with thanks to Age and ageingen_GB
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAging-
dc.subject.meshDrug Therapy-
dc.subject.meshEvidence-Based Medicine-
dc.subject.meshFrail Elderly-
dc.subject.meshHumans-
dc.subject.meshInappropriate Prescribing-
dc.subject.meshLife Expectancy-
dc.subject.meshPalliative Care-
dc.subject.meshPatient Selection-
dc.subject.meshPolypharmacy-
dc.subject.meshPractice Guidelines as Topic-
dc.subject.meshRisk Assessment-
dc.subject.meshSecondary Prevention-
dc.titlePharmacotherapy at the end-of-life.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, University College Cork, University Hospital, Wilton, Ireland. denis.omahony@hse.ieen_GB
dc.identifier.journalAge and ageingen_GB
dc.description.fundingNo fundingen
dc.description.provinceConnachten
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.